New York Fed Study Reveals Surging Gas Prices Disproportionately Impact LowerIncome Households Shell Receives Upgrade to Buy Following ARC Resources Deal Completion USChina Trade Talks Show Persistent Divergence at APEC SpaceX IPO Plans Signal Massive Investment in Rocket Technology and Artificial Intelligence US Productivity Growth Slows in Q4 as Labor Costs Rise Data Shows Aluminum Price Surge Amid Iran Conflict Pressures Major US Companies CRESY Q1 2026 Earnings Strong EPS of 61402 Drives Positive Market Reaction Outlook Therapeutics Q1 2026 Earnings EPS Misses Estimates but Stock Surges 29 Rexford Industrial Realty REXR Q1 2026 Earnings Strong EPS Beat Drives Surprise but Stock Slips FIP Q1 2026 Earnings Significant EPS Miss Weighs on Shares NRG Energy Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Reaction EL Q1 2026 Earnings Strong EPS Beat Drives DoubleDigit Stock Surge NVIDIA NVDA Retreats to 2126 as Market Weighs Sector Pressures Reinsurance Group of America 575 FixedtoFloating Debentures RZB Hold Steady at 2528 Amid Flat Trading Adams Diversified Equity Fund ADX Edges Higher Amid Steady Trading IDT Corporation IDT Inches Higher as Shares Hold Near Key Support Levels Brookfield Renewable Partners BEP Holds Steady as Renewable Energy Sector Faces Mixed Signals Kevin Warsh Appointed Fed Chair Pledges ReformOriented Agenda in SwearingIn Ceremony Saga Q1 2026 Earnings Negative EPS and Stock Decline Amidst Industry Headwinds Soren Acquisition Corp SORN Holds Steady at 992 Consolidation Phase Ahead Paramount Gold Nevada Corp PZG Slips 148 as Technical Indicators Suggest Potential Consolidation Synthetic FixedIncome Securities Inc STRATS Trust for PG Securities GJR Holds Steady at 2475 Amid Low Volatility CoastalSouth Bancshares COSO Holds Steady Near Key Support Level Niu Technologies NIU Slides 2 to 240 Key Support Levels Under Pressure Tivic Health Systems TIVC Holds Steady at 140 as Key Support and Resistance Levels Define Range PGIM High Yield Bond Fund ISD Edges Higher as Bond Market Stabilizes Aclaris Therapeutics ACRS Edges Higher Testing Resistance After Modest Uptick